Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Headache

Retrieve available abstracts of 346 articles:
HTML format

Single Articles

    June 2022
  1. TEPPER SJ, Grosberg B, Daniel O, Kuruvilla DE, et al
    Migraine treatment with external concurrent occipital and trigeminal neurostimulation-A randomized controlled trial.
    Headache. 2022 Jun 24. doi: 10.1111/head.14350.
    PubMed     Abstract available

  2. BERTELS Z, Mangutov E, Conway C, Siegersma K, et al
    Migraine and peripheral pain models show differential alterations in neuronal complexity.
    Headache. 2022 Jun 8. doi: 10.1111/head.14352.
    PubMed     Abstract available

  3. CHIANG CC, Chhabra N, Chao CJ, Wang H, et al
    Migraine with aura associates with a higher artificial intelligence: ECG atrial fibrillation prediction model output compared to migraine without aura in both women and men.
    Headache. 2022 Jun 8. doi: 10.1111/head.14339.
    PubMed     Abstract available

  4. PERO A, Pace A, Dhamoon MS
    Triptan medication use among patients with migraine with contraindications in the US.
    Headache. 2022 Jun 7. doi: 10.1111/head.14327.
    PubMed     Abstract available

  5. CASANOVA A, Vives-Mestres M, Donoghue S, Mian A, et al
    An observational study of self-reported migraine triggers and prospective evaluation of the relationships with occurrence of attacks enabled by a smartphone application (App).
    Headache. 2022 Jun 7. doi: 10.1111/head.14328.
    PubMed     Abstract available

  6. RICHER LP, Ali S, Johnson DW, Rosychuk RJ, et al
    A randomized trial of ketorolac and metoclopramide for migraine in the emergency department.
    Headache. 2022 Jun 7. doi: 10.1111/head.14307.
    PubMed     Abstract available

  7. BUOITE STELLA A, Filingeri D, Garascia G, D'Acunto L, et al
    Skin wetness sensitivity across body sites commonly affected by pain in people with migraine.
    Headache. 2022 Jun 7. doi: 10.1111/head.14323.
    PubMed     Abstract available

  8. GELFAND AA, Halker Singh RB, Robbins MS
    Worsening migraine: Another casualty of natural disasters.
    Headache. 2022 Jun 7. doi: 10.1111/head.14325.

  9. COWAN RP, Rapoport AM, Blythe J, Rothrock J, et al
    Diagnostic accuracy of an artificial intelligence online engine in migraine: A multi-center study.
    Headache. 2022 Jun 3. doi: 10.1111/head.14324.
    PubMed     Abstract available

    Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology, and management.
    Headache. 2022;62:650-656.
    PubMed     Abstract available

    May 2022
  11. EZZATI A, Fanning KM, Buse DC, Pavlovic JM, et al
    Predictive models for determining treatment response to nonprescription acute medications in migraine: Results from the American Migraine Prevalence and Prevention Study.
    Headache. 2022 May 11. doi: 10.1111/head.14312.
    PubMed     Abstract available

  12. LEE DA, Lee HJ, Park KM
    Normal glymphatic system function in patients with migraine: A pilot study.
    Headache. 2022 May 11. doi: 10.1111/head.14320.
    PubMed     Abstract available

  13. SCHWEDT TJ, Robert T, Dodick DW
    Treatment of chronic migraine with medication overuse: A perspective.
    Headache. 2022 May 6. doi: 10.1111/head.14314.

  14. HSU TW, Chen MH, Chu CS, Tsai SJ, et al
    Attention deficit hyperactivity disorder and risk of migraine: A nationwide longitudinal study.
    Headache. 2022 May 6. doi: 10.1111/head.14306.
    PubMed     Abstract available

  15. KHAYATA MJ, Farley S, Davis JK, Hornik CP, et al
    Beyond pain control: Outcome and treatment preferences in pediatric migraine.
    Headache. 2022 May 6. doi: 10.1111/head.14315.
    PubMed     Abstract available

  16. SCHIM JD, Anderson C, Brunner E, Hirman J, et al
    Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials.
    Headache. 2022 May 6. doi: 10.1111/head.14302.
    PubMed     Abstract available

  17. CARVALHO GF, Luedtke K, Pinheiro CF, Moraes R, et al
    Migraine and balance impairment: Influence of subdiagnosis, otoneurological function, falls, and psychosocial factors.
    Headache. 2022;62:548-557.
    PubMed     Abstract available

  18. ASHINA M, Tepper SJ, Brandes JL, Reuter U, et al
    Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Headache. 2022;62:624-633.
    PubMed     Abstract available

  19. LEIBOVIT-REIBEN Z, Ishii R, Dodick DW, Dumkrieger G, et al
    The impact of pre-morbid headaches on headache features and long-term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research.
    Headache. 2022;62:566-576.
    PubMed     Abstract available

  20. ZEBENHOLZER K, Gall W, Gleiss A, Pavelic AR, et al
    Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Headache. 2022;62:604-612.
    PubMed     Abstract available

  21. YOUSEF YENGEJ D, Nwaobi SE, Ferando I, Kechechyan G, et al
    Different characteristics of cortical spreading depression in the sleep and wake states.
    Headache. 2022;62:577-587.
    PubMed     Abstract available

    April 2022
  22. NAHMAN-AVERBUCH H, Schneider VJ 2nd, Lee GR, Peugh JL, et al
    New insight into the neural mechanisms of migraine in adolescents: Relationships with sleep.
    Headache. 2022 Apr 25. doi: 10.1111/head.14299.
    PubMed     Abstract available

  23. TU YH, Wang YF, Yuan H, Chen SP, et al
    Most bothersome symptoms in patients with migraine: A hospital-based study in Taiwan.
    Headache. 2022 Apr 25. doi: 10.1111/head.14308.
    PubMed     Abstract available

  24. VIG SJ, Garza J, Tao Y
    The use of erenumab for migraine prophylaxis during pregnancy: A case report and narrative review.
    Headache. 2022 Apr 25. doi: 10.1111/head.14305.
    PubMed     Abstract available

  25. OKAZAKI Y, Yoshida S, Kashima S, Koike S, et al
    Impact of the 2018 Japan Floods on prescriptions for migraine: A longitudinal analysis using the National Database of Health Insurance Claims.
    Headache. 2022 Apr 25. doi: 10.1111/head.14301.
    PubMed     Abstract available

  26. LIPTON RB, Goadsby PJ, Dodick DW, McGinley JS, et al
    Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention.
    Headache. 2022 Apr 25. doi: 10.1111/head.14295.
    PubMed     Abstract available

  27. BECKER WJ, Spacey S, Leroux E, Giammarco R, et al
    A real-world, observational study of erenumab for migraine prevention in Canadian patients.
    Headache. 2022 Apr 10. doi: 10.1111/head.14291.
    PubMed     Abstract available

  28. FERRARI MD, Zuurbier KWM, Barash S, Ning X, et al
    Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid.
    Headache. 2022 Apr 6. doi: 10.1111/head.14294.

  29. SILVESTRO M, Tessitore A, Orologio I, Battista G, et al
    Cluster headache pathophysiology: What we have learned from advanced neuroimaging.
    Headache. 2022;62:436-452.
    PubMed     Abstract available

    March 2022
  30. HARRIS L, L'Italien G, Kumar A, Seelam P, et al
    Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.
    Headache. 2022 Mar 28. doi: 10.1111/head.14289.
    PubMed     Abstract available

  31. SENG EK, Lipton RB
    Do behavioral treatments work for migraine prevention?
    Headache. 2022 Mar 16. doi: 10.1111/head.14290.

  32. BUSE DC, Gerstein MT, Houts CR, McGinley JS, et al
    Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study.
    Headache. 2022 Mar 16. doi: 10.1111/head.14274.
    PubMed     Abstract available

  33. CARVALHO GF, Becnel AR, Miske C, Szikszay TM, et al
    Postural control impairment in patients with headaches-A systematic review and meta-analysis.
    Headache. 2022;62:241-270.
    PubMed     Abstract available

    February 2022
  34. AILANI J, Winner P, Hartry A, Brevig T, et al
    Patient preference for early onset of efficacy of preventive migraine treatments.
    Headache. 2022 Feb 20. doi: 10.1111/head.14255.
    PubMed     Abstract available

  35. GRECO R, Demartini C, Zanaboni AM, Francavilla M, et al
    The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain.
    Headache. 2022 Feb 18. doi: 10.1111/head.14267.
    PubMed     Abstract available

  36. KLAN T, Brascher AK, Klein S, Diezemann-Prossdorf A, et al
    Assessing attack-related fear in headache disorders-Structure and psychometric properties of the Fear of Attacks in Migraine Inventory.
    Headache. 2022 Feb 18. doi: 10.1111/head.14272.
    PubMed     Abstract available

    The relationship of childhood adversity and migraine and the value of prospective studies.
    Headache. 2022 Feb 9. doi: 10.1111/head.14268.

  38. TEPPER SJ, Sheikh HU, Dougherty CO, Nahas SJ, et al
    Erenumab dosage for migraine prevention: An evidence-based narrative review with recommendations.
    Headache. 2022 Feb 9. doi: 10.1111/head.14266.
    PubMed     Abstract available

  39. KAWATA AK, Ladd MK, Lipton RB, Buse DC, et al
    Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials.
    Headache. 2022 Feb 8. doi: 10.1111/head.14258.
    PubMed     Abstract available

  40. DUDENEY J, Sharpe L, McDonald S, Menzies RE, et al
    Are psychological interventions efficacious for adults with migraine? A systematic review and meta-analysis.
    Headache. 2022 Feb 5. doi: 10.1111/head.14260.
    PubMed     Abstract available

  41. DI ANTONIO S, Castaldo M, Ponzano M, Bovis F, et al
    Trigeminal and cervical sensitization during the four phases of the migraine cycle in patients with episodic migraine.
    Headache. 2022 Feb 5. doi: 10.1111/head.14261.
    PubMed     Abstract available

  42. GOLLION C, Guidolin B, Lerebours F, Rousseau V, et al
    Migraine and large artery atherosclerosis in young adults with ischemic stroke.
    Headache. 2022 Feb 5. doi: 10.1111/head.14265.
    PubMed     Abstract available

  43. HAMMOND NG, Colman I, Orr SL
    Adverse childhood experiences and onset of migraine in Canadian adolescents: A cohort study.
    Headache. 2022 Feb 5. doi: 10.1111/head.14256.
    PubMed     Abstract available

  44. GIL YE, Lee MJ, Cho S, Chung CS, et al
    Effect of caffeine and caffeine cessation on cerebrovascular reactivity in patients with migraine.
    Headache. 2022 Feb 3. doi: 10.1111/head.14263.
    PubMed     Abstract available

  45. SHAO Q, Rascati KL, Barner JC, Lawson KA, et al
    Healthcare utilization and costs among patients with chronic migraine, episodic migraine, and tension-type headache enrolled in commercial insurance plans.
    Headache. 2022;62:141-158.
    PubMed     Abstract available

  46. AILANI J, Kuruppu DK, Rettiganti M, Oakes T, et al
    Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
    Headache. 2022;62:198-207.
    PubMed     Abstract available

    January 2022
  47. LIPTON RB, Nicholson RA, Reed ML, Araujo AB, et al
    Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.
    Headache. 2022 Jan 25. doi: 10.1111/head.14259.
    PubMed     Abstract available

  48. ARTEMENKO AR, Filatova E, Vorobyeva YD, Do TP, et al
    Migraine and light: A narrative review.
    Headache. 2022;62:4-10.
    PubMed     Abstract available

  49. ELSER H, Skajaa N, Ehrenstein V, Fuglsang CH, et al
    Cancer risk in patients with migraine: A population-based cohort study in Denmark.
    Headache. 2022;62:57-64.
    PubMed     Abstract available

    December 2021
  50. MASON BN, Kallianpur R, Price TJ, Akopian AN, et al
    Prolactin signaling modulates stress-induced behavioral responses in a preclinical mouse model of migraine.
    Headache. 2021 Dec 29. doi: 10.1111/head.14248.
    PubMed     Abstract available

  51. LIPTON RB, Gandhi P, Stokes J, Cala ML, et al
    Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: The Activity Impairment in Migraine Diary.
    Headache. 2021 Dec 28. doi: 10.1111/head.14229.
    PubMed     Abstract available

  52. AILANI J, Blumenfeld AM
    Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
    Headache. 2021 Dec 7. doi: 10.1111/head.14244.

  53. BURCH RC, Ailani J, Robbins MS
    The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Headache. 2021 Dec 7. doi: 10.1111/head.14245.

  54. OLIVEIRA ADP, Silva-Neto RP
    Circadian rhythmicity on red ear syndrome in a patient with migraine: A case report.
    Headache. 2021 Dec 7. doi: 10.1111/head.14242.
    PubMed     Abstract available

  55. GONZALEZ-MARTINEZ A, Trillo Senin S, Benavides Bernaldo de Queiros C, Casado Fernandez L, et al
    Clinical characteristics and perfusion-computed tomography alterations in a series of patients with migraine with aura attended as stroke code.
    Headache. 2021 Dec 3. doi: 10.1111/head.14243.
    PubMed     Abstract available

    November 2021
  56. CHARLES JA, Turner IM
    AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?
    Headache. 2021 Nov 28. doi: 10.1111/head.14232.

  57. MCALLISTER PJ, Turner I, Reuter U, Wang A, et al
    Timing and durability of response to erenumab in patients with episodic migraine.
    Headache. 2021 Nov 28. doi: 10.1111/head.14233.
    PubMed     Abstract available

  58. LEE JH, Shewale AR, Barthold D, Devine B, et al
    Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Headache. 2021 Nov 28. doi: 10.1111/head.14238.
    PubMed     Abstract available

  59. OZKAN E, Gursoy-Ozdemir Y
    Occipital bending in migraine with visual aura.
    Headache. 2021 Nov 28. doi: 10.1111/head.14240.
    PubMed     Abstract available

  60. GLADSTONE J, Chhibber S, Minhas J, Neish CS, et al
    Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
    Headache. 2021 Nov 22. doi: 10.1111/head.14218.
    PubMed     Abstract available

  61. KAZI F, Manyapu M, Fakherddine M, Mekuria K, et al
    Second-line interventions for migraine in the emergency department: A narrative review.
    Headache. 2021 Nov 22. doi: 10.1111/head.14239.
    PubMed     Abstract available

  62. CHARLES A, Nwaobi SE, Goadsby P
    Inflammation in migraine...or not...: A critical evaluation of the evidence.
    Headache. 2021 Nov 22. doi: 10.1111/head.14224.

  63. VYAS MV, Saposnik G, Lay C
    Migraine and sun avoidance behaviors in Canadian adults.
    Headache. 2021 Nov 2. doi: 10.1111/head.14227.

  64. RAGAB AH, Kishk NA, Hassan A, Yacoub O, et al
    Changes in migraine characteristics over 30 days of Ramadan fasting: A prospective study.
    Headache. 2021 Nov 2. doi: 10.1111/head.14231.
    PubMed     Abstract available

    Can we anticipate how Ramadan fasting will affect migraine?
    Headache. 2021;61:1463-1464.

  66. KELLY AM, Kuan WS, Chu KH, Kinnear FB, et al
    Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)-A multinational observational study.
    Headache. 2021;61:1539-1552.
    PubMed     Abstract available

    October 2021
  67. YUAN H, Curran JG, Keith SW, Hopkins MM, et al
    Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study.
    Headache. 2021 Oct 3. doi: 10.1111/head.14214.
    PubMed     Abstract available

  68. GALLARDO VJ, Alpuente A, Cerda-Company X, Torres-Ferrus M, et al
    The impact of a digital platform on migraine patient-centered outcome research. Evaluation of midolordecabeza.org, a headache website in Spanish.
    Headache. 2021 Oct 3. doi: 10.1111/head.14225.
    PubMed     Abstract available

  69. PRICE A, Sumner P, Powell G
    Subjective sensory sensitivity and its relationship with anxiety in people with probable migraine.
    Headache. 2021;61:1342-1350.
    PubMed     Abstract available

  70. NABITY PS, Jaramillo CA, Resick PA, McGeary CA, et al
    Persistent posttraumatic headaches and functioning in veterans: Injury type can matter.
    Headache. 2021;61:1334-1341.
    PubMed     Abstract available

  71. STRAUSS LD, Yugrakh MS, Kaplan KE, Minen MT, et al
    Headache infusion centers: A survey on treatments provided, infusion center operations, and barriers to developing new infusion centers.
    Headache. 2021;61:1364-1375.
    PubMed     Abstract available

    September 2021
  72. DODICK DW, Tepper SJ, Ailani J, Pannacciulli N, et al
    Risk of hypertension in erenumab-treated patients with migraine: Analyses of clinical trial and postmarketing data.
    Headache. 2021 Sep 30. doi: 10.1111/head.14208.
    PubMed     Abstract available

  73. KLEIN A, Schankin CJ
    Visual snow syndrome, the spectrum of perceptual disorders, and migraine as a common risk factor: A narrative review.
    Headache. 2021 Sep 27. doi: 10.1111/head.14213.
    PubMed     Abstract available

  74. MARMURA MJ, Diener HC, Cowan RP, Tepper SJ, et al
    Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.
    Headache. 2021 Sep 22. doi: 10.1111/head.14206.
    PubMed     Abstract available

    Memantine for migraine-Big promise but little evidence.
    Headache. 2021;61:1151-1152.

  76. SENG EK
    Stress and migraine: I know it when I see it.
    Headache. 2021;61:1153-1155.

  77. YALINAY DIKMEN P, Ertas M, Kosak S, Cimentepe C, et al
    Primary headaches among gender dysphoric female-to-male individuals: A cross-sectional survey on gender transition experience.
    Headache. 2021;61:1194-1206.
    PubMed     Abstract available

  78. HOULE TT, Deng H, Tegeler CH, Turner DP, et al
    Continuous updating of individual headache forecasting models using Bayesian methods.
    Headache. 2021;61:1264-1273.
    PubMed     Abstract available

  79. BREEN ID, Mangold AR, VanderPluym JH
    The evolving understanding of risk with calcitonin gene-related peptide monoclonal antibodies based on real-world data: A focus on hypertension and Raynaud phenomenon.
    Headache. 2021;61:1274-1276.

    Everything old is new again.
    Headache. 2021;61:1286.

    August 2021
  81. KIM SK, Nikolova S, Schwedt TJ
    Structural aberrations of the brain associated with migraine: A narrative review.
    Headache. 2021 Aug 18. doi: 10.1111/head.14189.
    PubMed     Abstract available

  82. SPIERINGS ELH, Ning X, Ramirez Campos V, Cohen JM, et al
    Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b
    Headache. 2021 Aug 10. doi: 10.1111/head.14196.
    PubMed     Abstract available

  83. VIVES-MESTRES M, Casanova A, Hershey AD, Orr SL, et al
    Perceived stress and pain severity in individuals with chronic migraine: A longitudinal cohort study using daily prospective diary data.
    Headache. 2021 Aug 9. doi: 10.1111/head.14199.
    PubMed     Abstract available

  84. ZHANG N, Woldeamanuel YW
    Medication overuse headache in patients with chronic migraine using cannabis: A case-referent study.
    Headache. 2021 Aug 9. doi: 10.1111/head.14195.
    PubMed     Abstract available

  85. TEPPER SJ, Lucas S, Ashina M, Schwedt TJ, et al
    Timing and durability of response to erenumab in patients with chronic migraine.
    Headache. 2021 Aug 7. doi: 10.1111/head.14193.
    PubMed     Abstract available

  86. SMITH TR, Winner P, Aurora SK, Jeleva M, et al
    STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD((R)) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.
    Headache. 2021 Aug 7. doi: 10.1111/head.14184.
    PubMed     Abstract available

  87. CARONNA E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P, et al
    Toward a better understanding of persistent headache after mild COVID-19: Three migraine-like yet distinct scenarios.
    Headache. 2021 Aug 7. doi: 10.1111/head.14197.
    PubMed     Abstract available

  88. COHEN F, Friedman BW
    A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis.
    Headache. 2021 Aug 7. doi: 10.1111/head.14185.
    PubMed     Abstract available

  89. MISTRY VM, Morizio PL, Pepin MJ, Bryan WE, et al
    Role of memantine in the prophylactic treatment of episodic migraine: A systematic review.
    Headache. 2021 Aug 5. doi: 10.1111/head.14186.
    PubMed     Abstract available

    July 2021
  90. SAKAI F, Suzuki N, Kim BK, Igarashi H, et al
    Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14169.
    PubMed     Abstract available

  91. SAKAI F, Suzuki N, Kim BK, Tatsuoka Y, et al
    Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients.
    Headache. 2021 Jul 29. doi: 10.1111/head.14178.
    PubMed     Abstract available

  92. BARBANTI P, Aurilia C, Cevoli S, Egeo G, et al
    Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Headache. 2021 Jul 26. doi: 10.1111/head.14194.
    PubMed     Abstract available

  93. ARCA KN, VanderPluym JH, Halker Singh RB
    Narrative review of neuroimaging in migraine with aura.
    Headache. 2021 Jul 26. doi: 10.1111/head.14191.
    PubMed     Abstract available

  94. THOMSEN AV, Sorensen MT, Ashina M, Hougaard A, et al
    Symptomatic migraine: A systematic review to establish a clinically important diagnostic entity.
    Headache. 2021 Jul 12. doi: 10.1111/head.14187.
    PubMed     Abstract available

  95. SAMPAIO ROCHA-FILHO PA, Albanes Oliveira Bernardo A
    The usefulness of osmophobia for the diagnosis of migraine in children and adolescents.
    Headache. 2021 Jul 4. doi: 10.1111/head.14175.

  96. ISHII R
    Should chronic migraine be defined by eight or more headache days per month?
    Headache. 2021;61:983-984.

  97. WELLS RE, Estave PM, Burch R, Haas N, et al
    The value of the patient perspective in understanding the full burden of migraine.
    Headache. 2021;61:985-987.

  98. MINEN MT, Szperka CL, Kaplan K, Ehrlich A, et al
    Telehealth as a new care delivery model: The headache provider experience.
    Headache. 2021;61:1123-1131.
    PubMed     Abstract available

  99. KUMAR G, Payne AM, Maag LM, MacDonald S, et al
    Efficacy of a pediatric headache infusion center: A single-center experience.
    Headache. 2021;61:1086-1091.
    PubMed     Abstract available

  100. CARLSEN LN, Rouw C, Westergaard ML, Nielsen M, et al
    Treatment of medication overuse headache: Effect and predictors after 1 year-A randomized controlled trial.
    Headache. 2021;61:1112-1122.
    PubMed     Abstract available

    June 2021
  101. AILANI J, Burch RC, Robbins MS
    The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
    Headache. 2021 Jun 23. doi: 10.1111/head.14153.
    PubMed     Abstract available

  102. TAKESHIMA T, Sakai F, Hirata K, Imai N, et al
    Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Headache. 2021 Jun 21. doi: 10.1111/head.14138.
    PubMed     Abstract available

  103. RIZZOLI PB, Grazzi L
    Adaptation of the management of chronic migraine patients with medication overuse to the suspension of treatment protocols during the COVID-19 pandemic: Lessons from a tertiary headache center in Milan-6-month results.
    Headache. 2021 Jun 21. doi: 10.1111/head.14140.

  104. BHARADWAJ VN, Porreca F, Cowan RP, Kori S, et al
    A new hypothesis linking oxytocin to menstrual migraine.
    Headache. 2021 Jun 14. doi: 10.1111/head.14152.
    PubMed     Abstract available

  105. BARBANTI P, Fofi L, Grazzi L, Vernieri F, et al
    Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project.
    Headache. 2021 Jun 14. doi: 10.1111/head.14123.
    PubMed     Abstract available

  106. GRAZZI L, Andrasik F, Rizzoli P, Bernstein C, et al
    Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation.
    Headache. 2021 Jun 11. doi: 10.1111/head.14139.
    PubMed     Abstract available

  107. ASHINA M, Cohen JM, Gandhi SK, Du E, et al
    Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
    Headache. 2021 Jun 11. doi: 10.1111/head.14127.
    PubMed     Abstract available

    Could osmophobia be a clinical diagnostic marker for migraine?
    Headache. 2021 Jun 9. doi: 10.1111/head.14148.

  109. KIM BK, Cho S, Kim HY, Chu MK, et al
    Validity and reliability of the self-administered Visual Aura Rating Scale questionnaire for migraine with aura diagnosis: A prospective clinic-based study.
    Headache. 2021 Jun 9. doi: 10.1111/head.14133.
    PubMed     Abstract available

  110. ISHII R, Schwedt TJ, Dumkrieger G, Lalvani N, et al
    Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.
    Headache. 2021 Jun 3. doi: 10.1111/head.14154.
    PubMed     Abstract available

  111. ESTAVE PM, Beeghly S, Anderson R, Margol C, et al
    Learning the full impact of migraine through patient voices: A qualitative study.
    Headache. 2021 Jun 3. doi: 10.1111/head.14151.
    PubMed     Abstract available

  112. SCHUSTER NM, Gasperi M
    Not just preaching to the CHOIR-A map for improving comprehensive care of patients with chronic migraine and comorbid non-cephalic pain.
    Headache. 2021;61:805-807.

  113. JOSHI S, Tepper SJ, Lucas S, Rasmussen S, et al
    A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.
    Headache. 2021;61:838-853.
    PubMed     Abstract available

  114. LIANG Z, Thomas L, Jull G, Minto J, et al
    Neck pain associated with migraine does not necessarily reflect cervical musculoskeletal dysfunction.
    Headache. 2021;61:882-894.
    PubMed     Abstract available

  115. NAHMAN-AVERBUCH H, Hershey AD, Peugh JL, King CD, et al
    The promise of mechanistic approaches to understanding how youth with migraine get better-An Editorial to the 2020 Members' Choice Award Paper.
    Headache. 2021;61:803-804.

  116. BARAD MJ, Sturgeon JA, Hong J, Aggarwal AK, et al
    Characterization of chronic overlapping pain conditions in patients with chronic migraine: A CHOIR study.
    Headache. 2021;61:872-881.
    PubMed     Abstract available

    May 2021
  117. POPOFF E, Johnston K, Croop R, Thiry A, et al
    Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Headache. 2021 May 22. doi: 10.1111/head.14128.
    PubMed     Abstract available

  118. CHIANG CC, Halker Singh R, Lalvani N, Shubin Stein K, et al
    Patient experience of telemedicine for headache care during the COVID-19 pandemic: An American Migraine Foundation survey study.
    Headache. 2021 May 21. doi: 10.1111/head.14110.
    PubMed     Abstract available

  119. LIPTON RB, Dodick DW, Ailani J, McGill L, et al
    Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Headache. 2021 May 20. doi: 10.1111/head.14120.
    PubMed     Abstract available

  120. SAKAI F, Takeshima T, Homma G, Tanji Y, et al
    Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Headache. 2021 May 15. doi: 10.1111/head.14122.
    PubMed     Abstract available

  121. ZIPLOW J
    The importance of studying comorbidities in migraine.
    Headache. 2021;61:697.

  122. GREENE KA
    The status of intravenous dihydroergotamine for pediatric headache: Status migrainosus and beyond.
    Headache. 2021;61:698-699.

    April 2021
  123. JAKATE A, Blumenfeld AM, Boinpally R, Butler M, et al
    Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14095.
    PubMed     Abstract available

  124. YIN JH, Lin YK, Yang CP, Liang CS, et al
    Prevalence and association of lifestyle and medical-, psychiatric-, and pain-related comorbidities in patients with migraine: A cross-sectional study.
    Headache. 2021 Apr 5. doi: 10.1111/head.14106.
    PubMed     Abstract available

  125. AURORA SK, Shrewsbury SB, Ray S, Hindiyeh N, et al
    A link between gastrointestinal disorders and migraine: Insights into the gut-brain connection.
    Headache. 2021 Apr 1. doi: 10.1111/head.14099.
    PubMed     Abstract available

  126. BUSE DC, Armand CE, Charleston L 4th, Reed ML, et al
    Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
    Headache. 2021 Apr 1. doi: 10.1111/head.14103.
    PubMed     Abstract available

  127. HODGSON SE, Harding AM, Bourke EM, Taylor DM, et al
    A prospective, randomized, double-blind trial of intravenous chlorpromazine versus intravenous prochlorperazine for the treatment of acute migraine in adults presenting to the emergency department.
    Headache. 2021 Apr 1. doi: 10.1111/head.14091.
    PubMed     Abstract available

  128. LIPTON RB, Cohen JM, Galic M, Seminerio MJ, et al
    Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.
    Headache. 2021;61:662-672.
    PubMed     Abstract available

    Comparing treatments in the emergency department: What works for migraine?
    Headache. 2021;61:567-568.

  130. HINES DM, Shah S, Multani JK, Wade RL, et al
    Erenumab patient characteristics, medication adherence, and treatment patterns in the United States.
    Headache. 2021;61:590-602.
    PubMed     Abstract available

    March 2021
  131. NAEGEL S, Burow P, Holle D, Stoevesandt D, et al
    Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke-like episodes syndrome: A case report.
    Headache. 2021 Mar 29. doi: 10.1111/head.14101.

  132. TRIVEDI M, Dumkrieger G, Chong CD, Dodick DW, et al
    Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research.
    Headache. 2021 Mar 29. doi: 10.1111/head.14100.
    PubMed     Abstract available

  133. SAKAI F, Takeshima T, Tatsuoka Y, Hirata K, et al
    Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Headache. 2021 Mar 25. doi: 10.1111/head.14096.
    PubMed     Abstract available

  134. LIU Y, Xu F, Wheaton AG, Greenlund KJ, et al
    The association between inflammatory bowel disease and migraine or severe headache among US adults: Findings from the National Health Interview Survey, 2015-2016.
    Headache. 2021 Mar 23. doi: 10.1111/head.14087.
    PubMed     Abstract available

  135. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    Baseline sleep quality, stress, and depressive symptoms, and subsequent headache occurrence in a six-week prospective cohort study of patients with episodic migraine.
    Headache. 2021 Mar 22. doi: 10.1111/head.14105.
    PubMed     Abstract available

  136. WITTEN A, Marotta D, Cohen-Gadol A
    Developmental innervation of cranial dura mater and migraine headache: A narrative literature review.
    Headache. 2021 Mar 22. doi: 10.1111/head.14102.
    PubMed     Abstract available

  137. COWAN RP, Gross NB, Sweeney MD, Sagare AP, et al
    Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen.
    Headache. 2021 Mar 16. doi: 10.1111/head.14088.
    PubMed     Abstract available

  138. BLUMENFELD AM, Goadsby PJ, Dodick DW, Hutchinson S, et al
    Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.
    Headache. 2021;61:422-429.
    PubMed     Abstract available

    February 2021
  139. ASHINA H, Moskowitz MA
    Shared biological foundations of post-traumatic headache and migraine.
    Headache. 2021 Feb 25. doi: 10.1111/head.14084.

  140. MCGINLEY JS, Wirth RJ, Pavlovic JM, Donoghue S, et al
    Between and within-woman differences in the association between menstruation and migraine days.
    Headache. 2021 Feb 19. doi: 10.1111/head.14058.
    PubMed     Abstract available

  141. MCGINLEY JS, Houts CR, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in preventive migraine clinical trials.
    Headache. 2021 Feb 18. doi: 10.1111/head.14069.
    PubMed     Abstract available

  142. SHAO Q, Rascati KL, Lawson KA, Wilson JP, et al
    Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021 Feb 18. doi: 10.1111/head.14071.
    PubMed     Abstract available

  143. KAWATA AK, Shah N, Poon JL, Shaffer S, et al
    Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
    Headache. 2021 Feb 16. doi: 10.1111/head.14053.
    PubMed     Abstract available

  144. GELFAND AA, Ross AC, Pavitt S, Szperka CL, et al
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency? A response.
    Headache. 2021 Feb 5. doi: 10.1111/head.14061.

  145. GELFAND AA, Poland G
    Migraine treatment and COVID-19 vaccines: no cause for concern.
    Headache. 2021 Feb 5. doi: 10.1111/head.14086.
    PubMed     Abstract available

    Once too many: Impact of emergency department opioid use on future health resource utilization among patients with migraine.
    Headache. 2021;61:229-230.

  147. BURCH R
    Outcomes in clinical trials for migraine: What should we measure and who should decide?
    Headache. 2021;61:227-228.

  148. HOUTS CR, McGinley JS, Nishida TK, Buse DC, et al
    Systematic review of outcomes and endpoints in acute migraine clinical trials.
    Headache. 2021;61:263-275.
    PubMed     Abstract available

  149. PINTO MJ, Guerrero AL, Costa A
    Botulinum toxin as a novel therapeutic approach for auriculotemporal neuralgia.
    Headache. 2021;61:392-395.
    PubMed     Abstract available

    January 2021
  150. SLAVIN M, Li H, Khatri M, Frankenfeld C, et al
    Dietary magnesium and migraine in adults: A cross-sectional analysis of the National Health and Nutrition Examination Survey 2001-2004.
    Headache. 2021 Jan 27. doi: 10.1111/head.14065.
    PubMed     Abstract available

  151. SPECK RM, Yu R, Ford JH, Ayer DW, et al
    Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine.
    Headache. 2021 Jan 22. doi: 10.1111/head.14031.
    PubMed     Abstract available

  152. NEIVA GR, Meira E Cruz M, Salles C
    Would chronotype change the impact of the relationship between early school schedules and adolescent migraine frequency?
    Headache. 2021 Jan 20. doi: 10.1111/head.14060.

  153. SCHWEDT TJ, Hentz JG, Sahai-Srivastava S, Spare NM, et al
    Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.
    Headache. 2021 Jan 12. doi: 10.1111/head.14056.
    PubMed     Abstract available

  154. PAVLOVIC JM, Yu JS, Silberstein SD, Reed ML, et al
    Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group.
    Headache. 2021 Jan 9. doi: 10.1111/head.14035.
    PubMed     Abstract available

  155. LIAMPAS I, Mylonas KS, Brotis A, Dervenis P, et al
    Serum lipid abnormalities in migraine: A meta-analysis of observational studies.
    Headache. 2021 Jan 4. doi: 10.1111/head.14039.
    PubMed     Abstract available

  156. O'BRIEN HL, Halker Singh RB
    Breaking down barriers to care: Understanding migraine knowledge gaps among women's healthcare providers.
    Headache. 2021;61:7-8.

  157. KARVOUNIDES D, Marzouk M, Ross AC, VanderPluym JH, et al
    The intersection of COVID-19, school, and headaches: Problems and solutions.
    Headache. 2021;61:190-201.
    PubMed     Abstract available

  158. BERTELS Z, Witkowski WD, Asif S, Siegersma K, et al
    A non-convulsant delta-opioid receptor agonist, KNT-127, reduces cortical spreading depression and nitroglycerin-induced allodynia.
    Headache. 2021;61:170-178.
    PubMed     Abstract available

    December 2020
  159. OSWALD JC, Schuster NM
    A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment.
    Headache. 2020 Dec 31. doi: 10.1111/head.14044.

  160. SPECTOR AR, Kerkow JF, Collins TA
    Sleep terrors prodromal for migraine headaches responsive to galcanezumab: A case report.
    Headache. 2020 Dec 31. doi: 10.1111/head.14055.

  161. CONNELLY MA, Boorigie ME
    Feasibility of using "SMARTER" methodology for monitoring precipitating conditions of pediatric migraine episodes.
    Headache. 2020 Dec 31. doi: 10.1111/head.14028.
    PubMed     Abstract available

  162. CHENG V, Billups SJ, Saseen JJ
    Prescribing practices of migraine-specific pharmacotherapy associated with emergency department use for migraine.
    Headache. 2020 Dec 30. doi: 10.1111/head.14029.
    PubMed     Abstract available

  163. VERHAAK AMS, Williamson A, Johnson A, Murphy A, et al
    Migraine diagnosis and treatment: A knowledge and needs assessment of women's healthcare providers.
    Headache. 2020 Dec 30. doi: 10.1111/head.14027.
    PubMed     Abstract available

  164. PRESSMAN AR, Buse DC, Jacobson AS, Vaidya SJ, et al
    The migraine signature study: Methods and baseline results.
    Headache. 2020 Dec 23. doi: 10.1111/head.14033.
    PubMed     Abstract available

  165. BURCH R, Rizzoli P, Loder E
    The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys.
    Headache. 2020 Dec 21. doi: 10.1111/head.14024.
    PubMed     Abstract available

  166. HAGAN KK, Li W, Mostofsky E, Bertisch SM, et al
    Prospective cohort study of routine exercise and headache outcomes among adults with episodic migraine.
    Headache. 2020 Dec 21. doi: 10.1111/head.14037.
    PubMed     Abstract available

  167. HERSHEY AD, Lin T, Gruper Y, Harris D, et al
    Remote electrical neuromodulation for acute treatment of migraine in adolescents.
    Headache. 2020 Dec 21. doi: 10.1111/head.14042.
    PubMed     Abstract available

  168. BARBANTI P, Aurilia C, Egeo G, Fofi L, et al
    Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Headache. 2020 Dec 18. doi: 10.1111/head.14032.
    PubMed     Abstract available

  169. TORABI SJ, Kasle DA, Savoca EL, Gottschalk CH, et al
    Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population.
    Headache. 2020 Dec 18. doi: 10.1111/head.14040.
    PubMed     Abstract available

  170. LIPTON RB, Buse DC, Dodick DW, Schwedt TJ, et al
    Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
    Headache. 2020 Dec 16. doi: 10.1111/head.14018.
    PubMed     Abstract available

  171. SMITH M, Nakamoto M, Crocker J, Tiffany Morden F, et al
    Early impact of the COVID-19 pandemic on outpatient migraine care in Hawaii: Results of a quality improvement survey.
    Headache. 2020 Dec 14. doi: 10.1111/head.14030.
    PubMed     Abstract available

  172. DIENER HC, Marmura MJ, Tepper SJ, Cowan R, et al
    Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Headache. 2020 Dec 13. doi: 10.1111/head.14036.
    PubMed     Abstract available

    November 2020
  173. GELFAND AA, Pavitt S, Ross AC, Szperka CL, et al
    Later high school start time is associated with lower migraine frequency in adolescents.
    Headache. 2020 Nov 25. doi: 10.1111/head.14016.
    PubMed     Abstract available

  174. NAHMAN-AVERBUCH H, Thomas PL, Schneider VJ 2nd, Chamberlin LA, et al
    Spatial aspects of pain modulation are not disrupted in adolescents with migraine.
    Headache. 2020 Nov 24. doi: 10.1111/head.14017.
    PubMed     Abstract available

  175. TIRITICCO M, Vanotti A, Mantica D, Coppola A, et al
    Migraine With Exclusive Olfactory Aura: Case Report and Literature Review.
    Headache. 2020 Nov 18. doi: 10.1111/head.14014.
    PubMed     Abstract available

  176. MINEN MT, Adhikari S, Padikkala J, Tasneem S, et al
    Smartphone-Delivered Progressive Muscle Relaxation for the Treatment of Migraine in Primary Care: A Randomized Controlled Trial.
    Headache. 2020 Nov 16. doi: 10.1111/head.14010.
    PubMed     Abstract available

  177. LIPTON RB, Cohen JM, Bibeau K, Galic M, et al
    Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
    Headache. 2020 Nov 11. doi: 10.1111/head.13997.
    PubMed     Abstract available

  178. POLK AN, Protti TA, Smitherman TA
    Allodynia and Disability in Migraine: The Mediating Role of Stress.
    Headache. 2020 Nov 9. doi: 10.1111/head.14012.
    PubMed     Abstract available

  179. DODICK DW, Gottschalk C, Cady R, Hirman J, et al
    Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing.
    Headache. 2020 Nov 9. doi: 10.1111/head.14007.
    PubMed     Abstract available

  180. PILATI L, Battaglia G, Di Stefano V, Di Marco S, et al
    Migraine and Sport in a Physically Active Population of Students: Results of a Cross-Sectional Study.
    Headache. 2020 Nov 7. doi: 10.1111/head.14015.
    PubMed     Abstract available

  181. GILL K, Chia VM, Hernandez RK, Navetta M, et al
    Rates of Vascular Events in Patients With Migraine: A MarketScan((R)) Database Retrospective Cohort Study.
    Headache. 2020 Nov 3. doi: 10.1111/head.14001.
    PubMed     Abstract available

  182. BUSE DC, McGinley JS, Lipton RB
    Predicting the Future of Migraine Attack Prediction.
    Headache. 2020;60:2125-2128.

  183. VGONTZAS A, Li W, Mostofsky E, Mittleman MA, et al
    The Sleep - Migraine Enigma: A Comment.
    Headache. 2020;60:2610.

  184. FORD JH, Kurth T, Starling AJ, Ayer DW, et al
    Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine.
    Headache. 2020;60:2304-2319.
    PubMed     Abstract available

    October 2020
  185. ANDERSON CC, Ray CA, Butler MR, Darken RS, et al
    Effects of Procedural Discomfort and Expectation of Benefit on Therapy Continuation in Chronic Migraine Patients Treated With OnabotulinumtoxinA.
    Headache. 2020 Oct 31. doi: 10.1111/head.14008.
    PubMed     Abstract available

  186. BOLAY H, Ozge A, Uluduz D, Baykan B, et al
    Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?
    Headache. 2020 Oct 30. doi: 10.1111/head.13998.
    PubMed     Abstract available

  187. KRYMCHANTOWSKI A, Jevoux C, Silva-Neto RP, Krymchantowski AG, et al
    Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions.
    Headache. 2020 Oct 27. doi: 10.1111/head.13999.
    PubMed     Abstract available

  188. BLUMENFELD AM, Silberstein SD
    Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice".
    Headache. 2020 Oct 27. doi: 10.1111/head.13996.

  189. SMITHERMAN TA, Tietjen GE, Schuh K, Skljarevski V, et al
    Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
    Headache. 2020 Oct 16. doi: 10.1111/head.13970.
    PubMed     Abstract available

  190. BUSE DC, Reed ML, Fanning KM, Bostic RC, et al
    Demographics, Headache Features, and Comorbidity Profiles in Relation to Headache Frequency in People With Migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Headache. 2020 Oct 14. doi: 10.1111/head.13966.
    PubMed     Abstract available

  191. TU S, Liew D, Ademi Z, Owen AJ, et al
    The Health and Productivity Burden of Migraines in Australia.
    Headache. 2020 Oct 7. doi: 10.1111/head.13969.
    PubMed     Abstract available

  192. HOLSTEEN KK, Hittle M, Barad M, Nelson LM, et al
    Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures.
    Headache. 2020 Oct 6. doi: 10.1111/head.13960.
    PubMed     Abstract available

  193. BEUTHIN J, Veronesi M, Grosberg B, Evans RW, et al
    Gluten-Free Diet and Migraine.
    Headache. 2020 Oct 6. doi: 10.1111/head.13993.
    PubMed     Abstract available

  194. GHANSHANI S, Chen C, Lin B, Duan L, et al
    Risk of Acute Myocardial Infarction, Heart Failure, and Death in Migraine Patients Treated with Triptans.
    Headache. 2020 Oct 5. doi: 10.1111/head.13959.
    PubMed     Abstract available

  195. TOMKINS E, Craven A, Ruttledge M
    Migraine and Headache Care in the Republic of Ireland: History and a Vision for the Future Influenced by the COVID-19 Pandemic.
    Headache. 2020 Oct 3. doi: 10.1111/head.13985.
    PubMed     Abstract available

    September 2020
  196. SWART ECS, Good CB, Henderson R, Manolis C, et al
    Identifying Outcome Measures for Migraine Value-Based Contracting Using the Delphi Method.
    Headache. 2020 Sep 30. doi: 10.1111/head.13978.
    PubMed     Abstract available

  197. CHENG S, Jenkins B, Limberg N, Hutton E, et al
    Erenumab in Chronic Migraine: An Australian Experience.
    Headache. 2020 Sep 29. doi: 10.1111/head.13968.
    PubMed     Abstract available

  198. HAMILTON KT, Halker Singh RB, Ailani J, Butterfield RJ, et al
    Migraine Treatment in Pregnancy: An American Headache Society Survey.
    Headache. 2020 Sep 29. doi: 10.1111/head.13974.

  199. FRIEDMAN BW, Irizarry E, Williams A, Solorzano C, et al
    A Randomized, Double-Dummy, Emergency Department-Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine.
    Headache. 2020 Sep 27. doi: 10.1111/head.13961.
    PubMed     Abstract available

  200. QUINTAS M, Neto JL, Sequeiros J, Sousa A, et al
    Going Deep into Synaptic Vesicle Machinery Genes and Migraine Susceptibility - A Case-Control Association Study.
    Headache. 2020 Sep 26. doi: 10.1111/head.13957.
    PubMed     Abstract available

  201. MARTINS B, Costa A
    Migraine Improvement During COVID-19 Pandemic - A Case Report on the Wonders of a Mask.
    Headache. 2020 Sep 23. doi: 10.1111/head.13964.

  202. ROBBLEE J, Devick KL, Mendez N, Potter J, et al
    Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Headache. 2020 Sep 13. doi: 10.1111/head.13951.
    PubMed     Abstract available

  203. VIVES-MESTRES M, Casanova A, Buse DC, Donoghue S, et al
    Patterns of Perceived Stress Throughout the Migraine Cycle: A Longitudinal Cohort Study Using Daily Prospective Diary Data.
    Headache. 2020 Sep 12. doi: 10.1111/head.13943.
    PubMed     Abstract available

  204. BHERING MARTINS L, Silva de Miranda A, Rodrigues AMDS, Braga Tibaes JR, et al
    Altered Serum Levels of Renin-Angiotensin System Markers in Migraine.
    Headache. 2020 Sep 2. doi: 10.1111/head.13949.
    PubMed     Abstract available

  205. GELFAND AA, Ross AC, Irwin SL, Greene KA, et al
    Melatonin for Acute Treatment of Migraine in Children and Adolescents: A Pilot Randomized Trial.
    Headache. 2020;60:1712-1721.
    PubMed     Abstract available

  206. TOPTAN T, Aktan C, Basari A, Bolay H, et al
    Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom.
    Headache. 2020;60:1788-1792.
    PubMed     Abstract available

    Persistent Headache and Persistent Anosmia Associated With COVID-19.
    Headache. 2020;60:1797-1799.

  208. PORTA-ETESSAM J, Matias-Guiu JA, Gonzalez-Garcia N, Gomez Iglesias P, et al
    Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals.
    Headache. 2020;60:1697-1704.
    PubMed     Abstract available

  209. BOBKER SM, Robbins MS
    COVID-19 and Headache: A Primer for Trainees.
    Headache. 2020;60:1806-1811.
    PubMed     Abstract available

  210. LIPTON RB, Seng EK, Chu MK, Reed ML, et al
    The Effect of Psychiatric Comorbidities on Headache-Related Disability in Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
    Headache. 2020;60:1683-1696.
    PubMed     Abstract available

    August 2020
  211. HOUTS CR, Wirth RJ, McGinley JS, Cady R, et al
    Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine.
    Headache. 2020 Aug 30. doi: 10.1111/head.13946.
    PubMed     Abstract available

  212. THEROUX LM, Cappa R, Mendoza A, Mallawaarachchi I, et al
    Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
    Headache. 2020 Aug 27. doi: 10.1111/head.13937.
    PubMed     Abstract available

  213. LAW EF, Blume H, Palermo TM
    Longitudinal Impact of Parent Factors in Adolescents With Migraine and Tension-Type Headache.
    Headache. 2020 Aug 27. doi: 10.1111/head.13939.
    PubMed     Abstract available

  214. BARBANTI P, Brighina F, Egeo G, Di Stefano V, et al
    Migraine as a Cortical Brain Disorder.
    Headache. 2020 Aug 26. doi: 10.1111/head.13935.
    PubMed     Abstract available

  215. BROESSNER G, Reuter U, Bonner JH, Dodick DW, et al
    The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving >/=50%, >/=75%, and 100% Response.
    Headache. 2020 Aug 26. doi: 10.1111/head.13929.
    PubMed     Abstract available

  216. RIESCO N, Cernuda-Morollon E, Martinez-Camblor P, Perez-Pereda S, et al
    Peripheral, Interictal Serum S100B Levels are Not Increased in Chronic Migraine Patients.
    Headache. 2020 Aug 17. doi: 10.1111/head.13919.
    PubMed     Abstract available

  217. SCHAETZ L, Rimner T, Pathak P, Fang J, et al
    Employee and Employer Benefits From a Migraine Management Program: Disease Outcomes and Cost Analysis.
    Headache. 2020 Aug 16. doi: 10.1111/head.13933.
    PubMed     Abstract available

  218. BERMAN G, Croop R, Kudrow D, Halverson P, et al
    Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Headache. 2020 Aug 16. doi: 10.1111/head.13930.
    PubMed     Abstract available

  219. RUSCHEWEYH R, Athwal B, Gryglas-Dworak A, Frattale I, et al
    Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Headache. 2020 Aug 14. doi: 10.1111/head.13925.
    PubMed     Abstract available

  220. KOW CS, Hasan SS
    The use of pharmacological preventive therapy for migraine with weight gain potential amid COVID-19 pandemic.
    Headache. 2020 Aug 13. doi: 10.1111/head.13945.
    PubMed     Abstract available

  221. PINHEIRO CF, Moraes R, Carvalho GF, Sestari L, et al
    The Influence of Photophobia on Postural Control in Patients With Migraine.
    Headache. 2020 Aug 13. doi: 10.1111/head.13908.
    PubMed     Abstract available

  222. NGUYEN BN, Singh S, Downie LE, McKendrick AM, et al
    Migraine Screening in Primary Eye Care Practice: Current Behaviors and the Impact of Clinician Education.
    Headache. 2020 Aug 7. doi: 10.1111/head.13920.
    PubMed     Abstract available

  223. CAPE S
    Access to Migraine Treatments in Ontario, Canada: A Review of the Ontario Drug Benefit Program.
    Headache. 2020 Aug 5. doi: 10.1111/head.13918.
    PubMed     Abstract available

  224. PEARL TA, Dumkrieger G, Chong CD, Dodick DW, et al
    Impact of Depression and Anxiety Symptoms on Patient-Reported Outcomes in Patients With Migraine: Results From the American Registry for Migraine Research (ARMR).
    Headache. 2020 Aug 4. doi: 10.1111/head.13911.
    PubMed     Abstract available

  225. SPECK RM, Collins EM, Lombard L, Ayer DW, et al
    A Qualitative Study to Assess the Content Validity of the 24-Hour Migraine Quality of Life Questionnaire in Patients with Migraine.
    Headache. 2020 Aug 3. doi: 10.1111/head.13915.
    PubMed     Abstract available

  226. ROGERS DG, Bond DS, Bentley JP, Smitherman TA, et al
    Objectively Measured Physical Activity in Migraine as a Function of Headache Activity.
    Headache. 2020 Aug 2. doi: 10.1111/head.13921.
    PubMed     Abstract available

    July 2020
  227. WATTIEZ AS, O'Shea SA, Ten Eyck P, Sowers LP, et al
    Patients With Vestibular Migraine are More Likely to Have Occipital Headaches than those With Migraine Without Vestibular Symptoms.
    Headache. 2020 Jul 25. doi: 10.1111/head.13898.
    PubMed     Abstract available

  228. FORBES RB, McCarron M, Cardwell CR
    Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis.
    Headache. 2020 Jul 15. doi: 10.1111/head.13907.
    PubMed     Abstract available

  229. CAROLI A, Klan T, Gaul C, Kubik SU, et al
    Types of Triggers in Migraine - Factor Structure of the Headache Triggers Sensitivity and Avoidance Questionnaire and Development of a New Short Form (HTSAQ-SF).
    Headache. 2020 Jul 11. doi: 10.1111/head.13896.
    PubMed     Abstract available

  230. TEPPER SJ, Vasudeva R, Krege JH, Rathmann SS, et al
    Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Headache. 2020 Jul 7. doi: 10.1111/head.13897.
    PubMed     Abstract available

  231. LIAMPAS I, Siokas V, Mentis AA, Aloizou AM, et al
    Serum Homocysteine, Pyridoxine, Folate, and Vitamin B12 Levels in Migraine: Systematic Review and Meta-Analysis.
    Headache. 2020 Jul 2. doi: 10.1111/head.13892.
    PubMed     Abstract available

  232. MINEN MT, Jaran J, Boyers T, Corner S, et al
    Understanding What People With Migraine Consider to be Important Features of Migraine Tracking: An Analysis of the Utilization of Smartphone-Based Migraine Tracking With a Free-Text Feature.
    Headache. 2020;60:1402-1414.
    PubMed     Abstract available

  233. SUZUKI K, Fujita H, Hirata K
    Parkinson's Disease and Headache: Is there a Relevant Relationship?
    Headache. 2020;60:1440-1441.

    June 2020
  234. BURSTEIN R, Blumenfeld AM, Silberstein SD, Manack Adams A, et al
    Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review.
    Headache. 2020 Jun 30. doi: 10.1111/head.13849.
    PubMed     Abstract available

  235. DANNO D, Wolf J, Ishizaki K, Kikui S, et al
    Cranial Autonomic Symptoms of Migraine in Japan: Prospective Study of 373 Migraine Patients at a Tertiary Headache Center.
    Headache. 2020 Jun 27. doi: 10.1111/head.13888.
    PubMed     Abstract available

  236. JAKATE A, Boinpally R, Butler M, Lu K, et al
    Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.
    Headache. 2020 Jun 23. doi: 10.1111/head.13862.
    PubMed     Abstract available

  237. KARSAN N, Bose PR, O'Daly O, Zelaya FO, et al
    Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack.
    Headache. 2020 Jun 22. doi: 10.1111/head.13865.
    PubMed     Abstract available

  238. RUSSO A, Silvestro M, Trojsi F, Bisecco A, et al
    Cognitive Networks Disarrangement in Patients With Migraine Predicts Cutaneous Allodynia.
    Headache. 2020 Jun 13. doi: 10.1111/head.13860.
    PubMed     Abstract available

  239. PORTA-ETESSAM J, Gonzalez-Garcia N, Matias-Guiu JA, Montero-Escribano P, et al
    Should we adapt the prescription criteria for specific treatments for migraine due to the Covid-19 pandemic?
    Headache. 2020 Jun 11. doi: 10.1111/head.13880.
    PubMed     Abstract available

  240. SINGH J, Ali A
    Headache as the Presenting Symptom in 2 Patients with COVID-19 and a History of Migraine: 2 Case Reports.
    Headache. 2020 Jun 10. doi: 10.1111/head.13890.
    PubMed     Abstract available

  241. CHAN TLH, Cowan RP, Woldeamanuel YW
    Calcitonin Gene-Related Peptide Receptor Antagonists (Gepants) for the Acute Treatment of Nausea in Episodic Migraine: A Systematic Review and Meta-Analysis.
    Headache. 2020 Jun 9. doi: 10.1111/head.13858.
    PubMed     Abstract available

  242. LOMBARD L, Ye W, Nichols R, Jackson J, et al
    A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment.
    Headache. 2020 Jun 8. doi: 10.1111/head.13835.
    PubMed     Abstract available

  243. ROBBINS L, Tropp-Bluestone M
    Evolution and Migraine.
    Headache. 2020 Jun 8. doi: 10.1111/head.13837.

  244. PEREZ-PEREDA S, Gonzalez-Quintanilla V, Madera J, Pascual J, et al
    Chronic Migraine With Apparent Loss of Response to Onabotulinum Toxin Type A Due to Local Nitroglycerin Treatment for an Anal Fissure: A Case Report.
    Headache. 2020 Jun 3. doi: 10.1111/head.13863.
    PubMed     Abstract available

  245. KEARNEY E, Collins T, Sengupta S
    De Novo Visual Aura Onset in a Migraineur on Galcanezumab-Gnlm.
    Headache. 2020 Jun 1. doi: 10.1111/head.13855.

  246. TEPPER D
    Lasmiditan for the acute treatment of migraine.
    Headache. 2020;60:1225-1226.

  247. VIGANO A, Mancini V, Mastria G, Di Piero V, et al
    Is it Useful to Do a Taxonomy of Complex Visual Symptoms in Migraine? A Comment on Coining the Pablo Picasso Syndrome.
    Headache. 2020;60:1200-1201.

  248. ALI A
    Delay in OnabotulinumtoxinA Treatment During the COVID-19 Pandemic-Perspectives from a Virus Hotspot.
    Headache. 2020;60:1183-1186.
    PubMed     Abstract available

    May 2020
  249. RUSSO A, Lavorgna L, Silvestro M, Abbadessa G, et al
    Readability Analysis of Online Headache and Migraine Information.
    Headache. 2020 May 28. doi: 10.1111/head.13818.
    PubMed     Abstract available

  250. GVANTSELADZE K, Do TP, Hansen JM, Shapiro RE, et al
    The Stereotypical Image of a Person With Migraine According to Mass Media.
    Headache. 2020 May 27. doi: 10.1111/head.13846.
    PubMed     Abstract available

  251. HINDIYEH NA, Zhang N, Farrar M, Banerjee P, et al
    The Role of Diet and Nutrition in Migraine Triggers and Treatment: A Systematic Literature Review.
    Headache. 2020 May 25. doi: 10.1111/head.13836.
    PubMed     Abstract available

  252. PELLESI L, Do TP, Ashina H, Ashina M, et al
    Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
    Headache. 2020 May 21. doi: 10.1111/head.13843.
    PubMed     Abstract available

  253. GIBBS SN, Shah S, Deshpande CG, Bensink ME, et al
    United States Patients' Perspective of Living With Migraine: Country-Specific Results From the Global "My Migraine Voice" Survey.
    Headache. 2020 May 5. doi: 10.1111/head.13829.
    PubMed     Abstract available

  254. SILVESTRO M, Tessitore A, Scotto di Clemente F, Tedeschi G, et al
    Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
    Headache. 2020 May 2. doi: 10.1111/head.13832.
    PubMed     Abstract available

  255. WELLS RE, Strauss LD
    The Value of Headache-Specific Recommendations During COVID-19.
    Headache. 2020;60:820-823.

  256. EGHTESADI M, Marquis-Gravel G
    Rethinking Our Cardiovascular Risk Assessment in the Younger Female Migraine Population.
    Headache. 2020;60:994-997.

    April 2020
  257. LIAMPAS I, Siokas V, Brotis A, Vikelis M, et al
    Endogenous Melatonin Levels and Therapeutic Use of Exogenous Melatonin in Migraine: Systematic Review and Meta-Analysis.
    Headache. 2020 Apr 30. doi: 10.1111/head.13828.
    PubMed     Abstract available

  258. GRAZZI L, Rizzoli P
    The Adaptation of Management of Chronic Migraine Patients With Medication Overuse to the Suspension of Treatment Protocols During the COVID-19 Pandemic: Lessons From a Tertiary Headache Center in Milan, Italy.
    Headache. 2020 Apr 30. doi: 10.1111/head.13825.

  259. BEGASSE DE DHAEM O, Gharedaghi MH, Rizzoli P
    Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice.
    Headache. 2020 Apr 25. doi: 10.1111/head.13823.
    PubMed     Abstract available

  260. NAHMAN-AVERBUCH H, Schneider VJ 2nd, Chamberlin LA, Kroon Van Diest AM, et al
    Alterations in Brain Function After Cognitive Behavioral Therapy for Migraine in Children and Adolescents.
    Headache. 2020 Apr 23. doi: 10.1111/head.13814.
    PubMed     Abstract available

  261. HAMMOND NG, Colman I
    The Role of Positive Health Behaviors in the Relationship Between Early Life Stress and Migraine.
    Headache. 2020 Apr 22. doi: 10.1111/head.13808.
    PubMed     Abstract available

  262. HOMMEL KA, Carmody J, Hershey AD, Holbein C, et al
    Digital Therapeutic Self-Management Intervention in Adolescents With Migraine: Feasibility and Preliminary Efficacy of "Migraine Manager".
    Headache. 2020 Apr 22. doi: 10.1111/head.13805.
    PubMed     Abstract available

  263. ALBANES OLIVEIRA BERNARDO A, Lys Medeiros F, Sampaio Rocha-Filho PA
    Osmophobia and Odor-Triggered Headaches in Children and Adolescents: Prevalence, Associated Factors, and Importance in the Diagnosis of Migraine.
    Headache. 2020 Apr 15. doi: 10.1111/head.13806.
    PubMed     Abstract available

    Inflammatory Milieu May Trigger Metabolic Changes in Migraine Attacks.
    Headache. 2020 Apr 15. doi: 10.1111/head.13799.

  265. FREDERIKSEN SD, Bekker-Nielsen Dunbar M, Snoer AH, Deen M, et al
    Serotonin and Neuropeptides in Blood From Episodic and Chronic Migraine and Cluster Headache Patients in Case-Control and Case-Crossover Settings: A Systematic Review and Meta-Analysis.
    Headache. 2020 Apr 15. doi: 10.1111/head.13802.
    PubMed     Abstract available

  266. VIEIRA A, van der Linde I, Bright P, Wilkins A, et al
    Preference for Lighting Chromaticity in Migraine With Aura.
    Headache. 2020 Apr 13. doi: 10.1111/head.13801.
    PubMed     Abstract available

  267. SILVESTRO M, Tessitore A, Tedeschi G, Russo A, et al
    Migraine in the Time of COVID-19.
    Headache. 2020 Apr 8. doi: 10.1111/head.13803.

  268. MINEN MT, Robbins MS, Loder E, Nahas S, et al
    Addressing the Crisis of Diagnosis and Management of Migraine in Primary Care: A Summary of the American Headache Society FrontLine Primary Care Advisory Board.
    Headache. 2020 Apr 8. doi: 10.1111/head.13797.

  269. TIETJEN GE, Maly EF
    Migraine and Ischemic Stroke in Women. A Narrative Review.
    Headache. 2020 Apr 4. doi: 10.1111/head.13796.
    PubMed     Abstract available

    March 2020
  270. FERNANDES L, Khan N, Dobson J, Randall M, et al
    Multiple Cranial Nerve Blocks as an Alternative Preventative Therapy for Chronic Migraine.
    Headache. 2020 Mar 30. doi: 10.1111/head.13792.
    PubMed     Abstract available

  271. SZPERKA CL, Ailani J, Barmherzig R, Klein BC, et al
    Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers.
    Headache. 2020 Mar 30. doi: 10.1111/head.13810.
    PubMed     Abstract available

  272. MINEN MT, Jalloh A, Begasse de Dhaem O, Seng EK, et al
    Behavioral Therapy Preferences in People With Migraine.
    Headache. 2020 Mar 23. doi: 10.1111/head.13790.
    PubMed     Abstract available

  273. MAKAR GS, Siegal T, Syrow L
    Stroke-Like Migraine Attacks After Radiation Therapy (SMART) Syndrome: A Rare, Reversible Complication of Radiation Therapy.
    Headache. 2020 Mar 23. doi: 10.1111/head.13786.

  274. GEORGE KM, Folsom AR, Sharrett AR, Mosley TH, et al
    Migraine Headache and Risk of Dementia in the Atherosclerosis Risk in Communities Neurocognitive Study.
    Headache. 2020 Mar 22. doi: 10.1111/head.13794.
    PubMed     Abstract available

  275. RODRIGUEZ-CASTRO E, Lagorio AN, Bejarano-Garcia A, Aguiar P, et al
    Prolonged Migraine Stuttering Aura: Structural, Functional, and Video Neuroimaging Study of an Atypical Migraine Aura. A Case Report.
    Headache. 2020 Mar 5. doi: 10.1111/head.13780.
    PubMed     Abstract available

    February 2020
  276. CRAWFORD MR, Luik AI, Espie CA, Taylor HL, et al
    Digital Cognitive Behavioral Therapy for Insomnia in Women With Chronic Migraines.
    Headache. 2020 Feb 28. doi: 10.1111/head.13777.
    PubMed     Abstract available

  277. FALLA K, Ronksley P, Noel M, Orr SL, et al
    Internalizing Symptoms in Pediatric Migraine: A Systematic Review Protocol.
    Headache. 2020 Feb 25. doi: 10.1111/head.13778.
    PubMed     Abstract available

  278. GRAZZI L, Rizzoli P
    Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off!
    Headache. 2020 Feb 25. doi: 10.1111/head.13776.

  279. ORNELLO R, Frattale I, Pistoia F, Sacco S, et al
    Erenumab Plus Subcutaneous Immunoglobulin in a Patient With Comorbid Chronic Migraine and Myasthenia Gravis.
    Headache. 2020 Feb 25. doi: 10.1111/head.13779.

  280. DODICK DW, Lipton RB, Ailani J, Halker Singh RB, et al
    Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
    Headache. 2020 Feb 19. doi: 10.1111/head.13766.
    PubMed     Abstract available

  281. CARONNA E, Gallardo VJ, Fonseca E, Gomez-Galvan JB, et al
    How Does Migraine Change After 10 Years? A Clinical Cohort Follow-Up Analysis.
    Headache. 2020 Feb 18. doi: 10.1111/head.13774.
    PubMed     Abstract available

  282. GOLLION C, Arribarat G, Ruidavets JB, Fabre N, et al
    Neuromelanin Locus Coeruleus MRI Contrast in Migraine With Aura.
    Headache. 2020 Feb 17. doi: 10.1111/head.13771.
    PubMed     Abstract available

  283. STUBBERUD A, Tronvik E, Olsen A, Gravdahl G, et al
    Biofeedback Treatment App for Pediatric Migraine: Development and Usability Study.
    Headache. 2020 Feb 13. doi: 10.1111/head.13772.
    PubMed     Abstract available

  284. LEWIS R, Ruiz A, Monteith T
    Reversible Lesion of the Corpus Callosum in a Patient With Migraine With Aura: A Case Study.
    Headache. 2020 Feb 11. doi: 10.1111/head.13768.
    PubMed     Abstract available

  285. WINNER PK, Kabbouche M, Yonker M, Wangsadipura V, et al
    A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine.
    Headache. 2020 Feb 9. doi: 10.1111/head.13754.
    PubMed     Abstract available

  286. ORR SL, Turner A, Kabbouche MA, Horn PS, et al
    The Profile and Prognosis of Youth With Status Migrainosus: Results From an Observational Study.
    Headache. 2020 Feb 7. doi: 10.1111/head.13767.
    PubMed     Abstract available

  287. ZHANG DG, Amin FM, Guo S, Vestergaard MB, et al
    Plasma Glucose Levels Increase During Spontaneous Attacks of Migraine With and Without Aura.
    Headache. 2020 Feb 7. doi: 10.1111/head.13760.
    PubMed     Abstract available

  288. LEE YH, Huang IH, Kang YN
    Do Treatment Strategies of Fremanezumab Have Similar Effect on Migraine?
    Headache. 2020;60:473-475.

    January 2020
  289. HOUGAARD A, Younis S, Iljazi A, Sugimoto K, et al
    Intravenous Endothelin-1 Infusion Does Not Induce Aura or Headache in Migraine Patients With Aura.
    Headache. 2020 Jan 29. doi: 10.1111/head.13753.
    PubMed     Abstract available

  290. RIGGINS N, Ehrlich A, Sawhney H, Dapkus L, et al
    Retrospective Chart Review of Intravenous Valproate Sodium as a Preventive Treatment for Patients With Chronic Migraine.
    Headache. 2020 Jan 27. doi: 10.1111/head.13756.
    PubMed     Abstract available

  291. PURDY RA
    Migraine and Other Primary Headaches.
    Headache. 2020 Jan 26. doi: 10.1111/head.13750.

  292. MINEN MT, Sahyoun G, Gopal A, Levitan V, et al
    A Pilot Randomized Controlled Trial to Assess the Impact of Motivational Interviewing on Initiating Behavioral Therapy for Migraine.
    Headache. 2020 Jan 24. doi: 10.1111/head.13738.
    PubMed     Abstract available

  293. DIENER HC
    The Risks or Lack Thereof of Migraine Treatments in Vascular Disease.
    Headache. 2020 Jan 22. doi: 10.1111/head.13749.
    PubMed     Abstract available

  294. CHONG CD, Aguilar M, Schwedt TJ
    Altered Hypothalamic Region Covariance in Migraine and Cluster Headache: A Structural MRI Study.
    Headache. 2020 Jan 22. doi: 10.1111/head.13742.
    PubMed     Abstract available

  295. SPROUSE BLUM AS, Couperus CJ, Rosen BJ, Haskin-Leahy LF, et al
    Familial "Diplegic" Migraine - Description of a Family With a Novel CACNA1A Mutation.
    Headache. 2020 Jan 22. doi: 10.1111/head.13741.
    PubMed     Abstract available

  296. PEARL TA, Dumkrieger G, Chong CD, Dodick DW, et al
    Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research.
    Headache. 2020 Jan 22. doi: 10.1111/head.13745.
    PubMed     Abstract available

  297. FALKENBERG K, Ronde Bjerg H, Yamani N, Olesen J, et al
    Sumatriptan Does Not Antagonize CGRP-Induced Symptoms in Healthy Volunteers.
    Headache. 2020 Jan 16. doi: 10.1111/head.13747.
    PubMed     Abstract available

  298. D'AMICO D, Grazzi L, Grignani E, Leonardi M, et al
    HEADWORK Questionnaire: Why Do We Need a New Tool to Assess Work-Related Disability in Patients With Migraine?
    Headache. 2020 Jan 13. doi: 10.1111/head.13735.
    PubMed     Abstract available

  299. DARSEY M, Kyros T, Wang V, Rizzoli PB, et al
    Intranasal 3% Tetracaine Plus 0.05% Oxymetazoline in the Management of Status Migrainosus.
    Headache. 2020 Jan 9. doi: 10.1111/head.13739.

  300. SCOTT BR, Uomoto JM, Barry ES
    Impact of Pre-Existing Migraine and Other Co-Morbid or Co-Occurring Conditions on Presentation and Clinical Course Following Deployment-Related Concussion.
    Headache. 2020 Jan 3. doi: 10.1111/head.13709.
    PubMed     Abstract available

  301. AILANI J, Lipton RB, Hutchinson S, Knievel K, et al
    Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.
    Headache. 2020;60:141-152.
    PubMed     Abstract available

  302. NYE B, Thadani V
    Migraine and Driving.
    Headache. 2020;60:13-14.

  303. RAPOPORT AM, Lin T, Tepper SJ
    Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine.
    Headache. 2020;60:229-234.
    PubMed     Abstract available

    December 2019
  304. EVANS RW, Burch RC, Frishberg BM, Marmura MJ, et al
    Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline.
    Headache. 2019 Dec 31. doi: 10.1111/head.13720.
    PubMed     Abstract available

  305. RICHMOND L, Schneider RP, Steffel J, Sandor PS, et al
    Case Report: New-Onset Retinal Migraine After Transseptal Catheterization.
    Headache. 2019 Dec 30. doi: 10.1111/head.13732.
    PubMed     Abstract available

  306. SPROUSE BLUM AS, Lavoie B, Haag M, Mawe SM, et al
    No Gastrointestinal Dysmotility in Transgenic Mouse Models of Migraine.
    Headache. 2019 Dec 26. doi: 10.1111/head.13724.
    PubMed     Abstract available

  307. ZHANG N, Houle T, Hindiyeh N, Aurora SK, et al
    Systematic Review: Acupuncture vs Standard Pharmacological Therapy for Migraine Prevention.
    Headache. 2019 Dec 24. doi: 10.1111/head.13723.
    PubMed     Abstract available

  308. MUNJAL S, Singh P, Reed ML, Fanning K, et al
    Most Bothersome Symptom in Persons With Migraine: Results From the Migraine in America Symptoms and Treatment (MAST) Study.
    Headache. 2019 Dec 14. doi: 10.1111/head.13708.
    PubMed     Abstract available

  309. HOUTS CR, Wirth RJ, McGinley JS, Gwaltney C, et al
    Content Validity of HIT-6 as a Measure of Headache Impact in People With Migraine: A Narrative Review.
    Headache. 2019 Dec 6. doi: 10.1111/head.13701.
    PubMed     Abstract available

  310. MINEN MT, Zhou K, Miller L
    A Brief Look at Urgent Care Visits for Migraine: The Care Received and Ideas to Guide Migraine Care in this Proliferating Medical Setting.
    Headache. 2019 Dec 4. doi: 10.1111/head.13717.
    PubMed     Abstract available

  311. TEPPER SJ, Silberstein SD, Rosen NL, Lipton RB, et al
    The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings.
    Headache. 2019 Dec 2. doi: 10.1111/head.13716.
    PubMed     Abstract available

    November 2019
  312. MANSOUR AG, Ahdab R, Daaboul Y, Korjian S, et al
    Vitamin K2 Status and Arterial Stiffness Among Untreated Migraine Patients: A Case-Control Study.
    Headache. 2019 Nov 25. doi: 10.1111/head.13715.
    PubMed     Abstract available

  313. SCHWEDT TJ, Digre K, Tepper SJ, Spare NM, et al
    The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.
    Headache. 2019 Nov 22. doi: 10.1111/head.13688.
    PubMed     Abstract available

  314. HORNIK CP, Gelfand AA, Szperka CL, Pezzuto T, et al
    Development of a Prospective Real-World Data Clinical Registry of Children and Adolescents With Migraine.
    Headache. 2019 Nov 22. doi: 10.1111/head.13714.
    PubMed     Abstract available

  315. KHAN FA, Mohammed AE, Poongkunran M, Chimakurthy A, et al
    Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience.
    Headache. 2019 Nov 22. doi: 10.1111/head.13713.
    PubMed     Abstract available

  316. OAKES TM, Kovacs R, Rosen N, Doty E, et al
    Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies.
    Headache. 2019 Nov 13. doi: 10.1111/head.13684.
    PubMed     Abstract available

  317. YOM KH, Ricca AM, Ko AC
    Orbital Mass in a Patient With Exacerbation of Chronic Migraine - A Case Report.
    Headache. 2019 Nov 13. doi: 10.1111/head.13698.

  318. DETKE HC, Millen BA, Zhang Q, Samaan K, et al
    Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies.
    Headache. 2019 Nov 11. doi: 10.1111/head.13691.
    PubMed     Abstract available

  319. WANG R, Nie X, Xu S, Zhang M, et al
    Interrelated Pathogenesis? Neuronal Intranuclear Inclusion Disease Combining With Hemiplegic Migraine.
    Headache. 2019 Nov 8. doi: 10.1111/head.13687.
    PubMed     Abstract available

  320. GONZALEZ-MARTINEZ A, Rodriguez Vazquez E, de la Red Gallego H, Garcia-Azorin D, et al
    Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine.
    Headache. 2019 Nov 6. doi: 10.1111/head.13693.
    PubMed     Abstract available

    A Popperian View on Anti-CGRP Biologics in Migraine.
    Headache. 2019 Nov 6. doi: 10.1111/head.13695.

  322. MICHELS L, Villanueva J, O'Gorman R, Muthuraman M, et al
    Interictal Hyperperfusion in the Higher Visual Cortex in Patients With Episodic Migraine.
    Headache. 2019 Nov 4. doi: 10.1111/head.13646.
    PubMed     Abstract available

  323. WINNER PK, Spierings ELH, Yeung PP, Aycardi E, et al
    Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
    Headache. 2019 Nov 1. doi: 10.1111/head.13654.
    PubMed     Abstract available

  324. TURNER SB, Rende EK, Szperka CL, Hershey AD, et al
    The Development of the Pediatric Migraine Action Plan (PedMAP).
    Headache. 2019;59:1671-1672.

  325. TURNER SB, Rende EK, Pezzuto T, Weaver S, et al
    Pediatric Migraine Action Plan (PedMAP).
    Headache. 2019;59:1871-1873.

  326. LODER EW, Tfelt-Hansen P
    Further Questioning of the Significance of the Gepants: A Response.
    Headache. 2019;59:1831.

  327. NGUYEN J, Hu D
    Further Questioning of the Significance of the Gepants.
    Headache. 2019;59:1829-1830.

    October 2019
  328. LIPTON RB, Munjal S, Brand-Schieber E, Tepper SJ, et al
    Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study.
    Headache. 2019 Oct 24. doi: 10.1111/head.13663.
    PubMed     Abstract available

  329. MELHADO EM, Thiers Rister HL, Galego DR, de Oliveira AB, et al
    Allodynia in Menstrually Related Migraine: Score Assessment by Allodynia Symptom Checklist (ASC-12).
    Headache. 2019 Oct 21. doi: 10.1111/head.13677.
    PubMed     Abstract available

  330. CONNELLY M, Sekhon S, Stephens D, Boorigie M, et al
    Enhancing Outpatient Dihydroergotamine Infusion With Interdisciplinary Care to Treat Refractory Pediatric Migraine: Preliminary Outcomes From the Comprehensive Aggressive Migraine Protocol ("CAMP").
    Headache. 2019 Oct 18. doi: 10.1111/head.13685.
    PubMed     Abstract available

  331. SAKAI F, Takeshima T, Tatsuoka Y, Hirata K, et al
    A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Headache. 2019 Oct 14. doi: 10.1111/head.13652.
    PubMed     Abstract available

  332. CHEN SP, Eikermann-Haerter K
    How Imaging Can Help Us Better Understand the Migraine-Stroke Connection.
    Headache. 2019 Oct 3. doi: 10.1111/head.13664.
    PubMed     Abstract available

  333. BURCH R
    Epidemiology and Treatment of Menstrual Migraine and Migraine During Pregnancy and Lactation: A Narrative Review.
    Headache. 2019 Oct 3. doi: 10.1111/head.13665.
    PubMed     Abstract available

  334. SLAVIN M, Li HA, Frankenfeld C, Cheskin LJ, et al
    What is Needed for Evidence-Based Dietary Recommendations for Migraine: A Call to Action for Nutrition and Microbiome Research.
    Headache. 2019;59:1566-1581.
    PubMed     Abstract available

  335. CHUA AL, Grosberg BM, Evans RW
    Status Migrainosus in Children and Adults.
    Headache. 2019;59:1611-1623.

    September 2019
  336. LEROUX E, Rothrock J
    Triptans for Migraine Patients With Vascular Risks: New Insights, New Options.
    Headache. 2019 Sep 30. doi: 10.1111/head.13656.

  337. SENG EK, Singer AB, Metts C, Grinberg AS, et al
    Does Mindfulness-Based Cognitive Therapy for Migraine Reduce Migraine-Related Disability in People with Episodic and Chronic Migraine? A Phase 2b Pilot Randomized Clinical Trial.
    Headache. 2019 Sep 26. doi: 10.1111/head.13657.
    PubMed     Abstract available

  338. GUTTA R, Valentini KJ, Kaur G, Farooqi AA, et al
    Management of Childhood Migraine by Headache Specialist vs Non-Headache Specialists.
    Headache. 2019 Sep 26. doi: 10.1111/head.13660.
    PubMed     Abstract available

  339. OZUDOGRU S, Neufeld A, Katz BJ, Baggaley S, et al
    Reduced Visual Quality of Life Associated with Migraine is Most Closely Correlated with Symptoms of Dry Eye.
    Headache. 2019 Sep 26. doi: 10.1111/head.13662.
    PubMed     Abstract available

  340. LEE HH, Chen CC, Ong JR, Lin YF, et al
    Association of rs2651899 Polymorphism in the Positive Regulatory Domain 16 and Common Migraine Subtypes: A Meta-Analysis.
    Headache. 2019 Sep 26. doi: 10.1111/head.13670.
    PubMed     Abstract available

  341. CERIANI CEJ, Wilhour DA, Silberstein SD
    Novel Medications for the Treatment of Migraine.
    Headache. 2019 Sep 26. doi: 10.1111/head.13661.
    PubMed     Abstract available

  342. ROTA E, Zucco R, Guerzoni S, Cainazzo MM, et al
    Migraine Awareness in Italy and the Myth of "Cervical Arthrosis".
    Headache. 2019 Sep 26. doi: 10.1111/head.13679.
    PubMed     Abstract available

  343. KNOL MJ, Loehrer EA, Wen KX, Bos D, et al
    Migraine Genetic Variants Influence Cerebral Blood Flow.
    Headache. 2019 Sep 26. doi: 10.1111/head.13651.
    PubMed     Abstract available

  344. ROTHROCK JF, Adams AM, Lipton RB, Silberstein SD, et al
    FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Headache. 2019 Sep 26. doi: 10.1111/head.13653.
    PubMed     Abstract available

  345. LIPTON RB, Hutchinson S, Ailani J, Reed ML, et al
    Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
    Headache. 2019 Sep 22. doi: 10.1111/head.13642.
    PubMed     Abstract available

  346. RAVN J, Chalmer MA, Oehrstroem EL, Kogelman LJA, et al
    Characterization of Familial and Sporadic Migraine.
    Headache. 2019 Sep 22. doi: 10.1111/head.13640.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.